A novel role for the fibrinogen Asn-Gly-Arg (NGR) motif in platelet function

Róisín Moriarty; Ciara A. McManus; Matthew Lambert; Thea Tilley; Marc Devocelle; Marian Brennan; Steven W. Kerrigan; Dermot Cox

doi:10.1160/TH14-04-0366

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2015; 113(02): 290-304
DOI: 10.1160/TH14-04-0366

Cellular Haemostasis and Platelets

Schattauer GmbH

A novel role for the fibrinogen Asn-Gly-Arg (NGR) motif in platelet function

Róisín Moriarty

¹Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland

,

Ciara A. McManus

¹Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland

,

Matthew Lambert

¹Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland

,

Thea Tilley

¹Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland

,

Marc Devocelle

²Centre for Synthesis and Chemical Biology, Department of Pharmaceutical and Medicinal Chemistry, Royal College of Surgeons in Ireland, Dublin, Ireland

,

Marian Brennan

¹Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland

,

Steven W. Kerrigan

¹Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland

,

Dermot Cox

¹Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland

› Author Affiliations

Abstract

Summary

The integrin α_IIbβ₃ on resting platelets can bind to immobilised fibrinogen resulting in platelet spreading and activation but requires activation to bind to soluble fibrinogen. α_IIbβ₃ is known to interact with the general integrin-recognition motif RGD (arginine–glycine–aspartate) as well as the fibrinogen-specific γ-chain dodecapeptide; however, it is not known how fibrinogen binding triggers platelet activation. NGR (asparagine–glycine–arginine) is another integrin-recognition sequence present in fibrinogen and this study aims to determine if it plays a role in the interaction between fibrinogen and α_IIbβ₃. NGR-containing peptides inhibited resting platelet adhesion to fibrinogen with an IC₅₀ of 175 μM but failed to inhibit the adhesion of activated platelets to fibrinogen (IC₅₀ > 500 μM). Resting platelet adhesion to mutant fibrinogens lacking the NGR sequences was reduced compared to normal fibrinogen under both static and shear conditions (200 s^-1). However, pre-activated platelets were able to fully spread on all types of fibrinogen. Thus, the NGR motif in fibrinogen is the site that is primarily responsible for the interaction with resting α_IIbβ₃ and is responsible for triggering platelet activation.

Keywords

Platelets - GPIIb-IIIa - fibrinogen - platelet activation

Full Text

References

References
1 Wei AH, Schoenwaelder SM, Andrews RK. et al. New insights into the haemostatic function of platelets. Br J Haematol 2009; 147: 415-430.
2 Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
3 Nachman RL, Leung LL. Complex formation of platelet membrane glycoproteins IIb and Ilia with fibrinogen. J Clin Invest 1982; 69: 263-269.
4 Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol 2010; 11: 288-300.
5 Shattil S, Kashiwagi H, Pampori N. Integrin signalling: the platelet paradigm. Blood 1998; 91: 1-14.
6 Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64: 1393-401.
7 Savage B, Ruggeri ZM. Selective recognition of adhesive sites in surface-bound fibrinogen by glycoprotein IIb-IIIa on nonactivated platelets. J Biol Chem 1991; 266: 11227-11233.
8 Li Z, Delaney MK, O’Brien KA. et al. Signalling During Platelet Adhesion and Activation. Arterioscler Thromb Vasc Biol 2010; 30: 2341-2349.
9 Mosesson MW, Siebenlist KR, Meh DA. The Structure and Biological Features of Fibrinogen and Fibrin. Ann NY Acad Sci 2001; 936: 11-30.
10 Walker JB, Nesheim ME. The Molecular Weights, Mass Distribution, Chain Composition, and Structure of Soluble Fibrin Degradation Products Released from a Fibrin Clot Perfused with Plasmin. J Biol Chem 1999; 274: 5201-5212.
11 Hawiger J, Kloczewiak M, Bednarek M. et al. Platelet receptor recognition domains on the alpha chain of human fibrinogen: structure-function analysis. Bio-chem 1989; 28: 2909-2914.
12 Pytela R, Pierschbacher M, Ginsberg M. et al. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors. Science 1986; 231: 1559-1562.
13 Farrell DH, Thiagarajan P, Chung DW. et al. Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proc Nat Acad Sci USA 1992; 89: 10729-10732.
14 Kloczewiak M, Timmons S, Hawiger J. Localisation of a site interacting with human platelet receptor on carboxy-terminal segment of human fibrinogen [gamma] chain. Biochem Biophys Res Comm 1982; 107: 181-187.
15 Smith JW, Ruggeri ZM, Kunicki TJ. et al. Interaction of integrins avb3 and gly-coprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites. J Biol Chem 1990; 265: 12267-12271.
16 Springer TA, Zhu J, Xiao T. Structural basis for distinctive recognition of fibri-nogen gammaC peptide by the platelet integrin alphaIIbbeta3. J Cell Biol 2008; 182: 791-800.
17 Farrell DH, Thiagarajan P. Binding of recombinant fibrinogen mutants to platelets. J Biol Chem 1994; 269: 226-231.
18 Rooney MM, Parise LV, Lord ST. Dissecting Clot Retraction and Platelet Aggregation. J Biol Chem 1996; 271: 8553-8555.
19 Holmbäck K, Danton M, Suh T. et al. Impaired platelet aggregation and sustained bleeding in mice lacking the fibrinogen motif bound by integrin alpha IIb beta 3. EMBO J 1996; 15: 5760-5771.
20 Podolnikova NP, Yakubenko VP, Volkov GL. et al. Identification of a Novel Binding Site for Platelet Integrins aIIbβ3 (GPIIbIIIa) and α5β1 in the yC-domain of Fibrinogen. J Biol Chem 2003; 278: 32251-32258.
21 Podolnikova NP, Gorkun OV, Loreth RM. et al. A Cluster of Basic Amino Acid Residues in the y370-381 Sequence of Fibrinogen Comprises a Binding Site for Platelet Integrin «IIb/3 (Glycoprotein IIb/IIIa). Biochemistry 2005; 44: 16920-16930.
22 Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the α5β1 integrin from phage display library. J Biol Chem 1993; 268: 20205-20210.
23 Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the α5β1 integrin from a phage display library. J Cell Biol 1994; 124: 373-380.
24 Arap W, Pasqualini R, Ruoslahti E. Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model. Science 1998; 279: 377-380.
25 Pasqualini R, Koivunen E, Kain R. et al. Aminopeptidase N Is a Receptor for Tumor-homing Peptides and a Target for Inhibiting Angiogenesis. Cancer Res 2000; 60: 722-727.
26 Grifman M, Trepel M, Speece P. et al. Incorporation of Tumor-Targeting Pep-tides into Recombinant Adeno-associated Virus Capsids. Mol Ther 2001; 03: 964-975.
27 Corti A, Curnis F, Arap W. et al. The neovasculature homing motif NGR: more than meets the eye. Blood 2008; 112: 2628-2635.
28 Curnis F, Arrigoni G, Sacchi A. et al. Differential Binding of Drugs Containing the NGR Motif to CD13 Isoforms in Tumor Vessels, Epithelia, and Myeloid Cells. Cancer Res 2002; 62: 867-874.
29 Coin I, Beyermann M, Bienert M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat Protocols 2007; 02: 3247-3256.
30 Kerrigan SW, Douglas I, Wray A. et al. A role for glycoprotein Ib in Streptococcus sanguis-induced platelet aggregation. Blood 2002; 100: 509-516.
31 Cox D, Maree AO, Dooley M. et al. Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers. Stroke 2006; 37: 2153-2158.
32 Cox D, Aoki T, Seki J. et al. Pentamidine is a specific, non-peptide, GPIIb/IIIa antagonist. Thromb Haemost 1996; 75: 503-509.
33 Kerrigan SW, Clarke N, Loughman A. et al. Molecular basis for Staphylococcus aureus-mediated platelet aggregate formation under arterial shear in vitro . Arte-rioscler Thromb Vasc Biol 2008; 28: 335-340..
34 Maguire PB, Ohlendieck K. Oligomerisation of sarcoplasmic reticulum Ca2+-ATPase from rabbit skeletal muscle. FEBS Letters 1996; 396: 115-118.
35 Deng WP, Nickoloff JA. Site-directed mutagenesis of virtually any plasmid by eliminating a unique site. Anal Biochem 1992; 200: 81-88.
36 Binnie C, Hettasch J, Strickland E. et al. Characterisation of purified recombi-nant fibrinogen: partial phosphorylation of fibrinopeptide A. Biochem 1993; 32: 107-113.
37 Lord ST, Strickland E, Jayjock E. Strategy for Recombinant Multichain Protein Synthesis: Fibrinogen B//-Chain Variants as Thrombin Substrates. Biochem 1996; 35: 2342-2348.
38 O’Brien KA, Gartner TK, Hay N. et al. ADP-Stimulated Activation of Akt During Integrin Outside-In Signalling Promotes Platelet Spreading by Inhibiting Glycogen Synthase Kinase-3//. Arterioscler Thromb Vasc Biol 2012; 32: 2232-2240.
39 Naik UP, Naik MU. Association of CIB with GPIIb/IIIa during outside-in signalling is required for platelet spreading on fibrinogen. Blood 2003; 102: 1355-1362.
40 Lee D, Fong KP, King MR. et al. Differential Dynamics of Platelet Contact and Spreading. Biophys J 2012; 102: 472-482.
41 Quinn MJ, Fullard J, Kerrigan S. et al. Characterisation of a ligand-attenuated binding site on glycoprotein IIb/IIIa. Thromb Haemost 2002; 88: 811-816.
42 Quinn M, Deering A, Stewart M. et al. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists. Circulation 1999; 99: 2231-2238.
43 Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimisation, and multithreading. J Comput Chem 2010; 31: 455-461.
44 Sanner M. Python: a programming language for software integration and development. J Mol Graph Model 1999; 17: 57-61.
45 Pasqualini R, Koivunen E, Ruoslahti E. [alpha]v Integrins as receptors for tumor targeting by circulating ligands. Nat Biotech 1997; 15: 542-546.
46 Martin P, Papayannopoulou T. HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science 1982; 216: 1233-1235.
47 Fitzgerald JR, Loughman A, Keane F. et al. Fibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcyRIIa receptor. Mol Microbiol 2006; 59: 212-230.
48 Xiao T, Takagi J, Coller BS. et al. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004; 432: 59-67.
49 Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010; 09: 804-820.
50 Cox D, Smith R, Quinn M. et al. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000; 36: 1514-1519.
51 Adamczyk Z, Cichocki B, Ekiel-Jezewska ML. et al. Fibrinogen conformations and charge in electrolyte solutions derived from DLS and dynamic viscosity measurements. J Coll Interf Sci 2012; 385: 244-257.
52 Adamczyk Z, Barbasz J, Cies la M. Mechanisms of Fibrinogen Adsorption at Solid Substrates. Langmuir 2011; 27: 6868-6878.
53 Podolnikova NP, Yakovlev S, Yakubenko VP. et al. The Interaction of Integrin «IIb//3 with Fibrin Occurs through Multiple Binding Sites in the «IIb //-Pro-peller Domain. J Biol Chem 2014; 289: 2371-2383.
54 Litvinov RI, Mekler A, Shuman H. et al. Resolving Two-dimensional Kinetics of the Integrin «IIb/3-Fibrinogen Interactions Using Binding-Unbinding Correlation Spectroscopy. J Biol Chem 2012; 287: 35275-35285.
55 Romaniuk MA, Croci DO, Lapponi MJ. et al. Binding of galectin-1 to «IIb//3 integrin triggers “outside-in” signals, stimulates platelet activation, and controls primary hemostasis. FASEB J 2012; 26: 2788-2798.
56 Bednar RA, Gaul SL, Hamill TG. et al. Identification of Low Molecular Weight GP IIb/IIIa Antagonists That Bind Preferentially to Activated Platelets. J Pharmacol Exp Therap 1998; 285: 1317-1326.
57 Mousa SA, Bozarth JM, Forsythe MS. et al. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: Role of plasma calcium levels. Cardiovasc Res 2000; 47: 819-826.
58 Kamphuisen PW, Lee AYY. Catheter-related thrombosis: lifeline or a pain in the neck?. ASH Education Program Book 2012; 2012: 638-644.
59 O’Horo J, Maki D, Krupp A. et al. Arterial Catheters as a Source of Bloodstream Infection: A Systematic Review and Meta-Analysis. Crit Care Med. 2014 in press.
60 Luft D, Schmoor C, Wilson C. et al. Central venous catheter-associated bloodstream infection and colonisation of insertion site and catheter tip. What are the rates and risk factors in haematology patients? Ann Hematol 2010; 89: 1265-1275.
61 Loughman A, Fitzgerald JR, Brennan MP. et al. Roles for fibrinogen, immuno-globulin and complement in platelet activation promoted by Staphylococcus aureus clumping factor A. Mol Microbiol 2005; 57: 804-818.
62 O’Brien L, Kerrigan SW, Kaw G. et al. Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. Mol Microbiol 2002; 44: 1033-1044.